Real-life Efficacy and Toxicity of Brentuximab-Vedotin Associated With Bendamustine in Patients With Relapsed or Refractory Hodgkin Lymphoma (HL-R2-B2)
Clinical trial NCT07145125 · COMPLETED
Trial details
- NCT number
- NCT07145125
- Sponsor
- University Hospital, Bordeaux
- Status
- COMPLETED
- Study type
- OBSERVATIONAL
- Start date
- 2025-02-01
- Primary completion
- 2025-08-21
- Enrollment
- 222
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.